Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00685100

Enrollment

Registered

2008-05-28

Start date

2004-01-31

Completion date

2007-01-31

Last updated

2015-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Age Related Macular Degeneration

Keywords

IVTA; CNV; age-related macular degeneration; PDT

Brief summary

Background: To identify characteristic morphological changes of the retina, their change over time and the association with visual function after combined photodynamic therapy (PDT) and intravitreal triamcinolone (IVTA). Methods: In this retrospective study, 40 patients (40 eyes) were treated with PDT and same day IVTA. Optical coherence tomography (OCT), fluorescein angiography (FA) and evaluation of distance visual acuity (VA) were performed. Main outcome measures were the anatomical changes within intra- and subretinal compartments and their detailed analysis and grading.

Interventions

OTHERPDT plus intravitreal triamcinolone

PDT plus intravitreal triamcinolone

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Inclusion criteria

* cnv secondary to age related macular degeneration

Exclusion criteria

* glaucoma, diabetic retinopathy

Design outcomes

Primary

Measure	Time frame	Description
visual acuity, central retinal thickness (CRT), choroidal perfusion and macular sensitivity (MS)	Day 1, Week 1, 4 and 12	Changes in macular sensitivity after reduced fluence photodynamic therapy combined with intravitreal triamcinolone Mean DLT decreased from 4.71 dB at baseline to 3.45 dB after 12 months in the SPDT + IVTA group (mean decrease 1.26 dB; p \> 0.05) and from 5.42 dB to 4.92 dB in the RPDT + IVTA group (mean decrease 0.5 dB; p \> 0.05). Absolute and relative scotoma sizes remained stable in both groups at 12 months (mean change 0 and -0.6 test-points; p \> 0.05). Mean DLT values and absolute scotoma sizes correlated well with early and late leakage areas in FA (r = -0.45 to -0.80, p \< 0.02). With regard to MS, RPDT + IVTA did not show significant benefits over SPDT + IVTA at 12 months. Macular sensitivity correlated well with angiographic outcomes.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026